<DOC>
	<DOCNO>NCT02603185</DOCNO>
	<brief_summary>This phase I study design 3 part randomize , placebo-controlled , sequential ascending-dose study healthy volunteer . The safety , tolerability pharmacokinetics ascend single multiple dose Hemay007 assess Part 1 Part 3 , respectively . Food effect follow single oral dose evaluate Part 2 .</brief_summary>
	<brief_title>PhaseⅠFirst-in-Human Study Hemay007 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>1 . Male female age 18 45 year ( inclusive ) . 2 . Body weight &gt; 45 kg female &gt; 50 kg male , Body Mass Index ( BMI ) 19 30 kg/m2 inclusive . 3 . Female participant return negative pregnancy test ( serum urine ) screen visit Day 1 . 4 . Female participant childbearing potential male partner must use highly effective method contraception/birth control ( method result low failure rate , i.e . le 1 % per year , use consistently correctly ) currently lactate , participant 's breast feed infant study , 3 month last dose study drug take . Examples acceptable form highly effective contraception include : Established use oral , injected implant hormonal method contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . Sterilised male partner ( appropriate postvasectomy documentation absence sperm ejaculate ) . True abstinence : When line participant 's preferred usual lifestyle . Examples nonacceptable method contraception include : Condoms alone double barrier Periodic abstinence ( e.g . calendar , ovulation , symptothermal , post ovulation ) Withdrawal Spermicide ( approve method contraception Australia ) Male participant female partner childbearing potential must agree use condom , addition female partner use another acceptable method contraception . Acceptable method may use list ) e ) , surgical sterilisation ( vasectomy ) screen visit 6 month postdose . For study , female consider nonchildbearing potential postmenopausal ≥6 month ' spontaneous amenorrhea surgically sterile ( e.g . bilateral tubal ligation , salpingectomy without oophorectomy , surgical hysterectomy , bilateral oophorectomy ) . 5 . Males must agree refrain donate sperm , blood plasma ( study ) participate study least 28 day last dose study drug . 6 . Understands willing , able likely fully comply study procedure restriction . 7 . Have voluntarily give write informed consent participate study . Exclusion Criteria： 1 . Medical Conditions 1 . A history clinically severe gastrointestinal , hepatic , renal , cardiovascular , dermatological , immunological , respiratory , endocrine , oncological , neurological , metabolic , psychiatric disease haematological disorder . 2 . A current recent medical history clinically significant medical disease surgery within 4 week screen visit . 3 . Have gastrointestinal , hepatic renal condition may influence drug absorption metabolism . 2 . Medications 1 . Current , within 14 day initial dose study drug , regular use prescription counter ( OTC ) medication ( paracetamol exception ) include herbal supplement . 2 . Use drug inhibits induces hepatic metabolism drug within 30 day plan study drug administration ( e.g . inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid omeprazole ; inhibitor SSRI antidepressant , cimetidine , diltiazem , macrolides , nitroimidazoles , sedative hypnotic , verapamil , fluoroquinolones antihistamine ) . 3 . Known allergy study medication component . 4 . Recent history ( within 6 month screen visit ) frequent alcohol consumption , define average intake great 14 unit alcohol per week ( 1 unit = 360 mL beer 45 mL spirit 40 % alcohol content , 150 mL wine ) . 5 . Participants , , within 3 month screen visit , smoke 1 cigarette equivalent use nicotinecontaining product . Participants unable abstain smoke use nicotinecontaining product study . 6 . Participants donate , plan donate &gt; 450 mL blood , donate plasma , within 12 week plan dose date . All participant advise donate either blood plasma least 6 week complete study . 7 . Clinically significant laboratory result screen prior first dose study drug.These laboratory test may repeat , abnormal first screening , medical reason believe result may inaccurate . If repeat test within reference range , participant may include investigator considers previous find compromise participant 's safety interfere interpretation safety data . As AST ALT , hepatic function index laboratory biochemical test≤1.5×ULN allow . 8 . Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody screen . 9 . Clinically significant abnormal 12lead ECG obtain screen prior first dose study drug , determine Principal Investigator delegate . 10 . Clinically significant abnormal vital sign obtain screen prior first dose study drug , determine Principal Investigator delegate . 11 . Use drug abuse within 3 month screen visit , unable abstain use drug abuse study period . 12 . A history alcohol abuse dependence within 12 month screen visit . 13 . Dietary habit food intolerance interfere requirement participant consume standardise diet whilst confine clinical unit . 14 . Participation another clinical trial receipt investigational drug within 3 month screen visit . Females unprotected sex male partner within 30 day prior screen visit . 15 . Pregnancy lactate female . Participants must compliant inclusion exclusion criterion unless , follow discussion Investigator Sponsor , conclude minor deviation clinical significance consider unlikely significant effect result study . The deviation date decision document CRF Study File .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Phase 1 , Healthy subject</keyword>
</DOC>